Azora Therapeutics, Inc. operates as a biopharmaceutical company that develops small molecule new chemical entities for the treatment of autoimmune and inflammatory diseases. It offers treatment for dermatology and gastroenterology. The company's pipeline includes AT177, a colon-targeted aryl hydrocarbon receptor (AhR)…
| Métrica | AZR | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 58.3% | — |
| Operating Margin | — | -31.5% | — |
| Net Margin | — | -30.9% | — |
| FCF Margin | — | -10.6% | — |
| ROE | -151.2% | -36.3% | -114.9% |
| ROA | -119.5% | -29.8% | -89.7% |
| Current Ratio | 4.42 | 2.68 | +1.74 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -119.5% | — |
| ✗Flujo de caja operativo positivo | −$6M | −$7M |
| ✓Rentabilidad sobre activos al alza | -119.5% | -261.6% |
| ✓Caja operativa/activos supera al ROA | -97.3% | ROA -119.5% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 4.42 | 4.16 |
| ✗Sin aumentar el nº de acciones | 1M | 0M |
| –Margen bruto al alza | — | — |
| –Rotación de activos al alza | — | — |
| Calidad del negocio | FY25 |
|---|---|
| ✗ROCE > 10 % | -147.8% |
Azora Therapeutics, Inc. (DE) cotiza a 3.74 USD y tiene una capitalización bursátil de $10M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud